18 completed. 18 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Completed 18 |
| Phase 2 | 4 | Completed 4 |
Follow Skin Abnormalities: new trials by email Literature Review of Skin Abnormalities trials Research Report on Skin Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis TMB-001, Matching Vehicle - Ichthyosis | Phase 3 | Completed | LEO Pharma | 153 | 2022-06-21 | 2026-05-22 |
| A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita QTORIN 3.9% rapamycin anhydrous gel, Vehicle - Pachyonychia Congenita | Phase 3 | Completed | Palvella Therapeutics, Inc. | 87 | 2021-11-29 | 2024-08-29 |
| A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa Open Label Topical Beremagene Geperpavec (B-VEC) - Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa | Phase 3 | Completed | Krystal Biotech, Inc. | 47 | 2021-05-25 | 2024-04-09 |
| VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita PTX-022 - Pachyonychia Congenita | Phase 3 | Completed | Palvella Therapeutics, Inc. | 36 | 2020-09-01 | 2024-08-29 |
| Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB Topical Beremagene Geperpavec, Placebo - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | Phase 3 | Completed | Krystal Biotech, Inc. | 31 | 2020-08-17 | 2023-02-17 |
| Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) EB-101 - Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | Phase 3 | Completed | Abeona Therapeutics, Inc | 11 | 2020-01-10 | 2022-12-05 |
| Pregabalin Treatment for RDEB Pain and Itch Pregabalin - Pain, Neuropathic, Itch | Phase 3 | Completed | The Hospital for Sick Children | 1 | 2019-08-07 | 2025-01-22 |
| Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita PTX-022, Placebo - Pachyonychia Congenita | Phase 2 / Phase 3 | Completed | Palvella Therapeutics, Inc. | 73 | 2019-04-01 | 2024-08-29 |
| RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS) ADX-102 1% Topical Dermal Cream (reproxalap), Vehicle of ADX-102 Topical Dermal Cream - Sjogren-Larsson Syndrome | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 11 | 2018-07-18 | 2023-02-09 |
| Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex Botulinic toxin, Placebo - Epidermolysis Bullosa Simplex | Phase 2 / Phase 3 | Completed | University Hospital, Toulouse | 18 | 2018-06-14 | 2026-09-21 |
| Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa Oleogel-S10, Control gel - Epidermolysis Bullosa | Phase 3 | Completed | Amryt Research Limited | 223 | 2017-03-29 | 2023-07-20 |
| Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE) Irbesartan, Placebo - Ehlers-Danlos Syndrome, Vascular Type | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 61 | 2016-01-01 | 2024-02-29 |
| ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa SD-101-6.0 cream, Placebo (SD-101-0.0) cream - Epidermolysis Bullosa | Phase 3 | Completed | Scioderm, Inc. | 169 | 2015-03-11 | 2020-04-09 |
| Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side - Lamellar Ichthyosis | Phase 3 | Completed | Centre Hospitalier Universitaire de Nice | 6 | 2010-10-01 | 2026-06-17 |
| Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) Rezular 15mg, Placebo, Rezular - Irritable Bowel Syndrome With Diarrhea | Phase 3 | Completed | AGI Therapeutics, Inc. | 711 | 2007-09-01 | 2009-06-11 |
| Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA Campath 1H, Cyclophosphamide, Fludarabine - Dyskeratosis Congenita, Aplastic Anemia | Phase 2 / Phase 3 | Completed | Masonic Cancer Center, University of Minnesota | 36 | 2007-08-01 | 2017-12-05 |
| Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar Ichthyosis Liarozole - Ichthyosis, Lamellar | Phase 2 / Phase 3 | Completed | Stiefel, a GSK Company | 98 | 2006-01-01 | 2011-09-26 |
| Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis monolaurin cream - Ichthyosis | Phase 3 | Completed | Cellegy Pharmaceuticals | 90 | 1996-09-01 | 2015-03-25 |
Epidermolysis Bullosa (4) · Epidermolysis Bullosa Dystrophica (3) · Pachyonychia Congenita (3) · Ichthyosis (2) · Ichthyosis, Lamellar (2) · Anemia, Aplastic (1) · Blister (1) · Dyskeratosis Congenita (1) · Ehlers-Danlos Syndrome, Type IV (1) · Epidermolysis Bullosa Simplex (1) · Ichthyosis Bullosa of Siemens (1) · Neuralgia (1) · Pruritus (1) · Rare Diseases (1) · Sjogren-Larsson Syndrome (1)
Congenital Abnormalities (18) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (18) · Skin and Connective Tissue Diseases (18) · Skin Diseases (17) · Genetic Diseases, Inborn (16) · Skin Diseases, Genetic (16) · Skin Diseases, Vesiculobullous (7) · Infant, Newborn, Diseases (6) · Keratosis (6) · Collagen Diseases (4) · Connective Tissue Diseases (4) · Ichthyosis (4) · Abnormalities, Multiple (3) · Ectodermal Dysplasia (3)
Alemtuzumab (1) · Antilymphocyte Serum (1) · Bone Marrow Transplantation (1) · Cyclophosphamide (1) · Drugs, Investigational (1) · Irbesartan (1) · Methylprednisolone (1) · Pregabalin (1) · Radiotherapy (1) · Skin Cream (1) · Stem Cell Transplantation (1) · Whole-Body Irradiation (1) · abobotulinumtoxinA (1) · episalvan (1) · fludarabine (1)
Palvella Therapeutics, Inc. (3) · Krystal Biotech, Inc. (2) · AGI Therapeutics, Inc. (1) · Abeona Therapeutics, Inc (1) · Aldeyra Therapeutics, Inc. (1) · Amryt Research Limited (1) · Assistance Publique - Hôpitaux de Paris (1) · Cellegy Pharmaceuticals (1) · Centre Hospitalier Universitaire de Nice (1) · LEO Pharma (1) · Masonic Cancer Center, University of Minnesota (1) · Scioderm, Inc. (1) · Stiefel, a GSK Company (1) · The Hospital for Sick Children (1) · University Hospital, Toulouse (1)
United States (12) · France (7) · Germany (4) · Italy (4) · Canada (3) · United Kingdom (3) · Australia (2) · Austria (2) · Israel (2) · Netherlands (2) · Serbia (2) · Spain (2) · Argentina (1) · Belgium (1) · Brazil (1)
David Hansen, MD (2) · Joyce Teng, MD (2) · Amy Paller, MD (1) · Carl R. Thornfeldt (1) · Chiaverini Christine, Dr (1) · David Chien, MD (1) · Jakub Tolar, M.D., Ph.D. (1) · Jean Tang, MD (1) · Johannes S Kern, MD PhD (1) · Juliette Mazereeuw-Hautier, MD (1) · Koen van Rossem, MD, PhD (1)
PMID 20383216, PMID 20825986, PMID 23630948, PMID 24102348, PMID 31186047, PMID 32576219, PMID 32693833, PMID 36516090, PMID 39441591, PMID 39906986, PMID 40220208, PMID 40570869, PMID 42205007
2014 (1), 2015 (1), 2016 (1), 2017 (1)